Despite treatment advances, kidney disease burden remained unchanged over the past decade ...

A new once-weekly insulin option has arrived in India, offering a potential alternative to daily basal insulin injections for ...

As weight loss injectables become more widely available, many people wonder whether metformin is now outdated or whether ...

A review highlights hearing loss as a hidden complication of type 2 diabetes. It notes that roughly 1 in 4 experience hearing ...

Type 1.5 diabetes is often mistaken for type 2. Here is how to tell the difference and why the diagnosis matters.

Novo Nordisk has launched Awiqli, the world's first once-weekly basal insulin, in India for adults with Type 1 and Type 2 diabetes. The shift from daily to weekly injections could ease treatment ...

The presence of certain bacteria in the gut microbiota, and fluctuations in a person's metabolism, can be seen in people who ...

Chronic kidney disease (CKD) is common, largely silent and serious. Most people who have the condition do not realize they ...

The NHS begins offering teplizumab, the first drug shown to delay type 1 diabetes and postpone insulin by nearly three years.

Danish drugmaker Novo Nordisk has launched Awiqli, the world’s first once-weekly basal insulin, in India. Here’s how it works ...

Type 2 diabetes remission is possible with early intervention, significant weight loss and evidence-based care, but it's not ...

Medtronic delivered $36.4B in revenue, the strongest growth in a decade, led by Cardiovascular and ablation solutions. Learn ...